Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIC246 (Letermovir) Phase 2b for HCMV Prophylaxis in Transplant Recipients
NCT01063829Phase 2Completed
- Sponsor
- AiCuris
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of letermovir in cytomegalovirus infection (CMV) (4 arms), sponsored by AiCuris. Primary endpoints: Number of Participants With HCMV Prophylaxis Failure at 84 days and Time to Onset of HCMV Prophylaxis Failure at 84 days. Started Mar 2010; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01063829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063829.